{"id":35712,"date":"2025-08-12T17:07:31","date_gmt":"2025-08-12T17:07:31","guid":{"rendered":"https:\/\/allonlinebanglanewspapers.com\/news\/cannabinoid-clinical-trial-pipeline-gains-momentum-50-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight\/"},"modified":"2025-08-12T17:07:31","modified_gmt":"2025-08-12T17:07:31","slug":"cannabinoid-clinical-trial-pipeline-gains-momentum-50-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight","status":"publish","type":"post","link":"https:\/\/allonlinebanglanewspapers.com\/news\/cannabinoid-clinical-trial-pipeline-gains-momentum-50-companies-lead-the-charge-in-pioneering-new-treatments-delveinsight\/","title":{"rendered":"Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight"},"content":{"rendered":"<div id=\"main-body-container\" itemprop=\"articleBody\">\n<p align=\"justify\">New York, USA, Aug.  12, 2025  (GLOBE NEWSWIRE) &#8212; <b>Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight<\/b><\/p>\n<p align=\"justify\"><b><i>Cannabinoids are specific chemical compounds found in cannabis, such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Research is increasingly supporting the efficacy of cannabinoids like CBD (cannabidiol) and THC (tetrahydrocannabinol) in treating a wide range of conditions, including mental health disorders, neurodegenerative diseases, and chronic inflammation.\u00a0<\/i><\/b><\/p>\n<p align=\"justify\">DelveInsight\u2019s <b>&#8216;<\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gp3HcXExh-0DcBlkUxlgjQ4sHUZfaZQ598MMTjdTPpTzP0GnxBHwE9UIJCSadf8Kl8N62tyoADwcdMyO4sgVEVejSK3ctQzk4W2mQtUT2muT2xmGjimrlCq0s99qMdiVL7NLdZIUwyA3Q38gBiGtdw5lOpe0kIC_x8PU4yHWJAO3KqwbZon76er9Nnrw_xU0csxdojEclglswiavfibwGlw3NkXmcrQe3txCQAnWB37LMXDl3bAs5aZzdOLFrJTtMSysGKCuFO-An9s_sBnGIg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Cannabinoid Pipeline Insight 2025<\/b><\/a><b>&#8216;<\/b> report provides comprehensive global coverage of pipeline cannabinoid therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the cannabinoid pipeline domain.<\/p>\n<p align=\"justify\"><b>Key Takeaways from the Cannabinoid Pipeline Report<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">DelveInsight\u2019s      cannabinoid pipeline report depicts a robust space with<b> 50+ <\/b>active      players working to develop <b>55+ <\/b>pipeline cannabinoid drugs.\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Key      cannabinoid companies such as <b>Zynerba Pharmaceuticals, Incannex      Healthcare, IGC Pharma, INC., SciSparc, Biopharmaceutical Research      Company, Polyrizon, SciSparc, Innocan Pharma Corporation<\/b><b>, Apurano Pharmaceuticals,<\/b><b> Artelo Biosciences,      Inc., Octavian Therapeutics, Avata Biosciences, <\/b>and others are      evaluating new cannabinoid drugs to improve the\u00a0treatment landscape.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Promising      pipeline cannabinoid therapies, such as <b>ZYN-002, IHL-675A, IGC-AD1,      SCI-110, BRC-002, SCI-160, Cannabidiol-loaded LPT, AP-707, ART27.13,      OCT461201, AVAT 022, <\/b>and others, are in different phases of      cannabinoid clinical trials.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In      July 2025, MIRA Pharmaceuticals announced positive preclinical data      demonstrating that Mira-55, the Company\u2019s proprietary non-psychotropic      marijuana analog, delivered morphine-comparable pain relief in a validated      model of inflammatory pain-without causing local inflammation.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In      June 2025, InMed Pharmaceuticals announced new preclinical data      demonstrating that INM-901 significantly reduces inflammation in ex vivo      models of neuroinflammation, further supporting its potential as a      therapeutic candidate in Alzheimer\u2019s disease.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In      March 2025, Corbus Pharmaceuticals Holdings announced the dosing of the      first subject in the single ascending dose \/ multiple ascending dose      (SAD\/MAD) portion of the Phase I trial of CRB-913 cannabinoid type-1 (CB1)      receptor inverse agonist drug for the treatment of obesity. The study is      being conducted in the United States under an open IND.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In      January 2025, IGC Pharma, Inc. announced that its ongoing Phase II trial      for agitation in Alzheimer\u2019s disease has been officially named CALMA      (Calming Agitation in Alzheimer\u2019s).\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In      December 2024, Biopharmaceutical Research Company (BRC), announced that      the US Food and Drug Administration (FDA) granted Orphan Drug Designation      for the treatment of Complex Regional Pain Syndrome (CRPS) to BRC-002,      which is being investigated in an investigator-initiated clinical Phase I      trial.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">In      September 2024, IGC Pharma, Inc. announced data that reinforces the      therapeutic potential of IGC-AD1 as a disease-modifying treatment for      Alzheimer&#8217;s disease. The data highlights IGC-AD1&#8217;s promising effects on      tau tangles and spatial memory. These results build on earlier data      demonstrating IGC-AD1&#8217;s potential to reduce amyloid plaque.<\/li>\n<\/ul>\n<p align=\"justify\">Request a sample and discover the recent advances in cannabinoid drugs @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gp3HcXExh-0DcBlkUxlgjQ4sHUZfaZQ598MMTjdTPpTV6xxkfaC73g-kkJivfoXBt-maaw3kE8ni6ZSOB5FHA2OrGl-Qm6-L9A_LywsOPlje_A3BMoBxvmbdMix7lKXDB_Qqicja4TmtS1qWXaivNyBqZsw9Ya-QWbEegmp1Xm0Q6TDDCWSAuWSZHuP_j6Z52HcapHnjavUDjwMTRqJ49-MexYSPq6V1hL8IBltEwij8WqLtfjsKoQ0McvM4lJd9\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Cannabinoid Pipeline Report<\/b><\/a><\/p>\n<p align=\"justify\">The cannabinoid pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage cannabinoid drugs, inactive and dormant assets, a comprehensive assessment of driving and restraining factors, and an assessment of opportunities and risks in the cannabinoid clinical trial landscape.\u00a0<\/p>\n<p align=\"justify\"><b>Cannabinoid Overview<\/b><\/p>\n<p align=\"justify\">Cannabinoids refer to a wide range of chemical substances that interact with the endocannabinoid system, a complex network of receptors and signaling molecules responsible for regulating vital bodily functions such as pain perception, mood, appetite, and immune system activity. These compounds can either be naturally sourced from the cannabis plant or created synthetically. The most extensively studied cannabinoids are tetrahydrocannabinol (THC), known for its mind-altering effects, and cannabidiol (CBD), recognized for its therapeutic benefits without causing intoxication. Cannabinoids are being explored for their potential in treating numerous health conditions, including epilepsy, chronic pain, inflammation, and nausea, driving significant scientific interest and drug development.<\/p>\n<p align=\"justify\">Cannabinoids are generally categorized into three primary types:<\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Phytocannabinoids,      which occur naturally in the cannabis plant and include well-known      compounds like THC, CBD, and cannabigerol (CBG). These substances interact      with cannabinoid receptors in the body to produce various physiological      effects.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\">Endocannabinoids,      such as anandamide and 2-arachidonoylglycerol (2-AG), are molecules      produced by the human body that help regulate essential functions like      mood, appetite, and pain response.<\/li>\n<li style=\"margin-top:0in; margin-bottom:12pt; text-align:justify;\">Synthetic cannabinoids are      laboratory-engineered chemicals designed to replicate or modify the      actions of natural cannabinoids. While they are used in research and      therapeutic applications, some unauthorized synthetic variants have been      linked to harmful side effects.<\/li>\n<\/ul>\n<p align=\"justify\">The cannabis plant itself contains an estimated 80 to 100 cannabinoid compounds, along with around 300 other non-cannabinoid substances. Among these, delta-9-tetrahydrocannabinol (THC) is the most recognized for producing cannabis\u2019s psychoactive effects, while cannabidiol (CBD) is valued for its medicinal properties.<\/p>\n<p align=\"justify\">Therapeutically, cannabinoids have demonstrated the ability to influence the endocannabinoid system to help restore physiological balance. CBD, a non-psychoactive cannabinoid, has gained FDA approval for treating rare epilepsy forms like Lennox-Gastaut and Dravet syndromes through the drug Epidiolex. Additionally, it shows promise in managing conditions such as anxiety, inflammation, and neurodegenerative diseases. THC has proven effective for relieving chronic pain, reducing chemotherapy-related nausea and vomiting, and enhancing appetite in individuals with HIV\/AIDS. Furthermore, a combination of THC and CBD is under investigation for treating multiple sclerosis and certain cancer-related pain.<\/p>\n<p align=\"justify\">Beyond THC and CBD, other cannabinoids such as cannabigerol (CBG) and cannabinol (CBN) are being studied for their therapeutic potential in conditions like glaucoma and insomnia. Synthetic cannabinoids, including FDA-approved medications like nabilone and dronabinol, provide standardized dosing options for managing nausea and appetite loss. Ongoing research continues to explore the potential of cannabinoids in treating autoimmune disorders, post-traumatic stress disorder (PTSD), and opioid addiction, highlighting their promise as safer alternatives or complementary therapies in modern medicine.<\/p>\n<p align=\"justify\"><\/p>\n<p align=\"justify\">Find out more about cannabinoid drugs @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gp3HcXExh-0DcBlkUxlgjRKYC4l4jaqQg69uGOulwNLRyYF2r3Yk06iIXv7T3HY6hpnVqOmjcjNxEow9oWelM-tj_L4zwe7VxF4wSE24WhZQB4Gu8nqORSPQoSrG9RICtzjDW1PFgI5i-I2gQxzv5q9gJzj_91Fe73njP3xYpeDhj8LZA1fW3Ih3V47xgMLu3AVAB1szPUU9ypHvE-k_gTJsPWOqnziywaYxkJHzqQPAASE6u7whC9Cd_ApENXoD\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Cannabinoid Treatment<\/b><\/a><\/p>\n<p align=\"justify\"><b>A snapshot of the Pipeline Cannabinoid Drugs mentioned in the report:<\/b><\/p>\n<table style=\"border-collapse: collapse; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Drugs<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Company<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Phase\u00a0<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>Indication<\/b><\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \"><b>RoA<\/b><\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">ZYN-002<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Zynerba Pharmaceuticals<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">III<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Fragile X syndrome<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Transdermal<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">SCI-110<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">SciSparc<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">II<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Agitation; Alzheimer&#8217;s disease, Gilles de la   Tourette&#8217;s syndrome, Sleep apnoea syndrome<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Oral<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">IGC-AD1<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">IGC Pharma, INC<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">II<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Alzheimer disease<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Oral<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">BRC-002<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Biopharmaceutical Research Company<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">I<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Complex Regional Pain Syndrome<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Oral<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Cannabidiol-loaded LPT<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Innocan Pharma Corporation<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Preclinical<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Epilepsy, Pain<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Unspecified<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">Learn more about the emerging cannabinoid therapies @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gp3HcXExh-0DcBlkUxlgjQaAhtkduQjiyfDytO58ppdKAEPP3GS3js-UlZutHMJoewuvyOakdGVD7kq8JS-4j2kSAdYYhHdvRVzULwMB2tQBpHgevlVA3Jiu6Hiz6j9Orz27l_lqe4Eo6nBOKxtJ3Aowo49o-gVW4H9b0WTVBLzQmMhGP0fedDHNXgTcjsZ8GPClT8GFfFCYosrfYNAyITJOETnlb23yF_Y6YxAJHn1ybySwhCONitvuj7MF-8uFIxBYG9rS26SGn9IVrZB7qw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Cannabinoid Clinical Trials<\/b><\/a><\/p>\n<p align=\"justify\"><b>Cannabinoid Therapeutics Assessment<\/b><\/p>\n<p align=\"justify\">The\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Nw1G6ryYUWhbX85pquwsc3trnj_uDE3sqVUxNQQOmV2kcSrs3j6hOv36QLqxEdR_PTgTON8_DBH7f5dAnaB8JvOfxOuNSMFDwhI-FCxxlkuOiUv4iLmdvHPWZua0TVsz5Ia4rw73Vhkp_v_4nYgmHcTN8NGZ3RC15AvF9AtA_iOEI74nc22yHD_c-KUT9PeQnHrrk0QJXGWs-sc9GHrY5-GesBMWOOWI9tVRLmr4JExny6YNS-CUPO62fUaCB1qA\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>cannabinoid pipeline<\/b><\/a>\u00a0report proffers an integral view of the emerging cannabinoid therapies segmented by stage, product type, molecule type, route of administration, and mechanism of action.<\/p>\n<p align=\"justify\"><b>Scope of the Cannabinoid Pipeline Report\u00a0<\/b><\/p>\n<ul type=\"disc\">\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Coverage<\/b>:\u00a0Global\u00a0<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Therapeutic      Assessment By Product Type: <\/b>Mono, Combination, Mono\/Combination<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Therapeutic      Assessment By Clinical Stages: <\/b>Discovery, Pre-clinical, Phase I,      Phase II, Phase III<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Therapeutics Assessment<\/b> <b>By Route      of Administration:<\/b> Intravenous, Subcutaneous, Oral, Intramuscular<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Therapeutics Assessment<\/b> <b>By      Molecule Type<\/b>: Monoclonal antibody, Small molecule, Peptide<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Key Cannabinoid Companies<\/b>: Zynerba Pharmaceuticals, Incannex Healthcare, IGC      Pharma, INC., SciSparc, Biopharmaceutical Research Company, Polyrizon,      SciSparc, Innocan Pharma Corporation, Apurano Pharmaceuticals, Artelo      Biosciences, Inc., Octavian Therapeutics, Avata Biosciences, and others.<\/li>\n<li style=\"margin-top:0in; margin-bottom:0.0001pt; text-align:justify;\"><b>Key Cannabinoid Pipeline Therapies<\/b>: ZYN-002,      IHL-675A, IGC-AD1, SCI-110, BRC-002, SCI-160, Cannabidiol-loaded LPT, AP-707,      ART27.13, OCT461201, AVAT 022, and others.<\/li>\n<\/ul>\n<p align=\"justify\">Dive deep into rich insights for new cannabinoid treatments, visit @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gp3HcXExh-0DcBlkUxlgjUU3NJdopPGYhgt6jhWBVWPHLl6_7PuJ4DOqs0oxJB3Mi9rsey7JxfF9vgzTGnMwMeqhf1b-nJFrZzdmVk17FpmmkamJG_zuGE83Yl8JRds8vXBqRnMRPXhojyoGSEMZh6IjGBNnRbdUtr8LJPd6mjqCUndwgRqmhjn36erRjoZ6xd4eOD6_jlfyxIlOcMjGonhEZdU9yKMw__rPHxJSRDf4oFOpcfWLoMUfDnCnYRTE\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Cannabinoid Drugs<\/b><\/a><\/p>\n<p align=\"justify\"><b>Table of Contents<\/b><\/p>\n<table style=\"border-collapse: collapse; border-collapse:collapse ;\">\n<tr>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">1.<\/td>\n<td style=\"border-top: solid black 1pt ; border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Cannabinoid Pipeline Report Introduction<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">2.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Cannabinoid Pipeline Report Executive Summary<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">3.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Cannabinoid Pipeline: Overview<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">4.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Analytical Perspective In-depth Commercial Assessment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">5.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Cannabinoid Clinical Trial Therapeutics<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">6.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Cannabinoid Pipeline: Late-Stage Products (Pre-registration)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">7.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Cannabinoid Pipeline: Late-Stage Products (Phase III)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">8.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Cannabinoid Pipeline: Mid-Stage Products (Phase II)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">9.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Cannabinoid Pipeline: Early-Stage Products (Phase I)<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">10.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Cannabinoid Pipeline Therapeutics Assessment<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">11.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Inactive Products in the Cannabinoid Pipeline<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">12.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Company-University Collaborations (Licensing\/Partnering)   Analysis<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">13.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Companies<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">14.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Key Products in the Cannabinoid Pipeline<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">15.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Unmet Needs<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">16.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Market Drivers and Barriers<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">17.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Future Perspectives and Conclusion<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">18.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Analyst Views<\/td>\n<\/tr>\n<tr>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; border-left: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">19.<\/td>\n<td style=\"border-right: solid black 1pt ; border-bottom: solid black 1pt ; text-align: justify ;  vertical-align: middle; vertical-align: top ; \">Appendix<\/td>\n<\/tr>\n<\/table>\n<p align=\"justify\">For further information on the cannabinoid pipeline therapeutics, reach out @ <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gp3HcXExh-0DcBlkUxlgjdr9NcJW99vdn4PNzB79nF9UVoK2zwM0QgsIW1OpuoD00zLANo5f1OO7yW3bxEzxIYRMONfDIzER2Acp1YICYqvo74YWb3Cvw1ThKrGDLp4DaPevj2AONe8bTsEPpHjiBt3lLjXxYvLJXNaRNqXdVctm78PToUN0a76RYOT01EffQwezo3wrL8gUsuihDUv0NOz5bNvz0IXiJpBFr6lyIxOdlQlQCjA_uULGTtLA7B-t\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Cannabinoid Therapeutics<\/b><\/a><\/p>\n<p align=\"justify\"><b>Related Reports<\/b><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gp3HcXExh-0DcBlkUxlgjbK86moe940AceZ_BLuLgJes6Ek5FyrHpSiKTr9snD-FTjVuW_lpUB3F9kjwYhnmC5GUdRKIApQdx7NJFeY9sPJopaQko1rorqSy_vDR71zz-ACy15JIFXUd7w3TuwZh6XRJrZW8pjJNcQEbWMSzDwk6iYfSQhTRomGFm7j4jF9f6d5ix9x85UIUXDDzroivC-zF0LZYzQlUO9KFT2jOW-LUH4ei1fnlA683GCqWN0E4yL8PtD0rVsLMprOCFOUyTQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Cannabinoid Agonist Pipeline<\/b><\/a><\/p>\n<p align=\"justify\"><b>Cannabinoid Agonist Pipeline Insight <\/b><b>\u2013 2025<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cannabinoid agonist companies, including <b>Apurano Pharmaceuticals, IGC Pharma, Inc., Artelo Biosciences, Inc., NeuroTherapia, Oxford Cannabinoid Technologies Holdings, SciSparc, Mira Pharmaceuticals, InMed Pharmaceuticals, Corbus Pharmaceuticals,\u00a0 <\/b>among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gp3HcXExh-0DcBlkUxlgjVBq1uHlkgZuozKG21QLqd1vHMevmnAQnQH3Y6HbHO4RvGsYoTo9XK_1fXowUDwd3rp_9ta2JPicnhq4dabYHQJo3o1h6I5xpnbiGz8u2YazU8ZrjKglBQNjRE3wHwV3sS4wz5yxCw1Glax0Nl2yS-1GPe29evQD-I3xtkVtWvTwogzeVnMjF3yoHL8UIG2agUZ_fp6bwiGPDkOLdwvSzB3Rhay5kAUTj1hunb2l96DbWgHJOJclZ1suzThlLym7XFdyXMSk1rkITHGsd0Ok1Ct87tFKNO2WXOsEGpgaktaaR6dPCSesO2LJ6J-KqXkowQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Cannabinoid Receptor CB1 Inverse Agonists Pipeline<\/b><\/a><\/p>\n<p align=\"justify\"><b>Cannabinoid Receptor CB1 Inverse Agonists Pipeline Insight <\/b><b>\u2013 2025<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cannabinoid receptor CB1 inverse agonists companies, including <b>Corbus Pharmaceuticals, Inversago Pharma, Goldfinch Bio, Stero Biotechs, Beckley Canopy Therapeutics, Artelo Biosciences,\u00a0 <\/b>among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gp3HcXExh-0DcBlkUxlgjVBq1uHlkgZuozKG21QLqd3rEumaSrwLq52slYyuQD76in9BexVI9dM8kY3RGaRmSLAuzL1h3qaDkx1GnGNAddEaxPJnCrVxmpm_JFuSV7LtbuGLDvZr3WOHQnxW17FD6YhXsy1JK1SmVw3ZVgJRwQLXcDSHaOXjUJ3o3tjP8Ubk1_ruFQ2LNAIp6B8BtlSFVuIeX39zT3Ap15hg_3u0IuGJMBVvkMBNFTlYn0LQPg5wvy1zKmAUFuB_MiOXWZHSqSYv1IuDvcDVHUVeNkEf_998SX71CdD47ClrpyaSL7413-jeNpnyRpBaU4YQ4WiWdQ==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Cannabinoid Receptor Type 1 (CB1) Antagonist Pipeline<\/b><\/a><\/p>\n<p align=\"justify\"><b>Cannabinoid Receptor Type 1 (CB1) Antagonist Pipeline Insight <\/b><b>\u2013 2025<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key cannabinoid receptor type 1 (CB1) antagonist companies, including <b>Skye Biologics Holdings, Aelis Farma,\u00a0 <\/b>among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VdmCfGCL6Z2YGpenAb3iwKt5gw1z-plV6UxjlZ5wvd7oDJ3yxb9-f1N27AyjAQnelbg-p8BQQKjXDiyNJNEW9mopo5aTmBrR5QWaqfAoWcZ5eynHt7lg838jBV6y5OHFx5Z32aWjGOxKOy9-obTvnU1sNxl-42pkzSFjWJ0FgCVOuwYY-eCe7lI0ekZ4KWA7nXk9QDDmagtGlJ7AJR_Yv5rgVpuZJnW36L8leK2tFcXARZFd_5xqXBGY6alGtVw5\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Alzheimer&#8217;s Disease Market<\/b><\/a><\/p>\n<p align=\"justify\"><b>Alzheimer&#8217;s Disease Market Insights, Epidemiology, and Market Forecast <\/b><b>\u2013 2034 <\/b>report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Alzheimer&#8217;s disease companies, including <b>AB Science, Alzheon Inc., AriBio Co., Ltd., AgeneBio, Inc., Anavex Life Sciences Corp., Annovis Bio, Inc., Cerecin, BioVie, Cassava Sciences, Novo Nordisk, Eli Lilly, Neurim Pharmaceuticals, Suven Life Sciences, Bristol Myers Squibb, Karuna Therapeutics, T3D Therapeutics, Inc., Lexeo Therapeutics, Axsome Therapeutics, Inc., Araclon Biotech S.L., Eisai Co., Ltd., TauRx Therapeutics, TrueBinding, Inc., AC Immune SA, Johnson &amp; Johnson, Longeveron Inc., Vaccinex Inc., IGC Pharma LLC<\/b><b>,<\/b> among others.<\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=VdmCfGCL6Z2YGpenAb3iwJBJVvnIuu5X0kUWU3mXhzKGr2skcjQQPbGHRWrhZdYhjQZZ_BD_Ww_42E1Ul0U3FOQTMHHhin0l85zkEfLlamO8oQYnAdx_kgS4C_mN-w5m5v-S60l_Vj2eMkprm-7Kxxpd-Thh4tuPIKOfS2Wa50InAgFkpr8kHtfhyVzo6kldbRUJoXBvBLBQ8tPIfx0KY2RHk3KUOFh9vjMmy1WUOL5AT4ODyT1s-lgSsGZ21zeVjAC9Pic0ZdtDWhW-rOjVTg==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Alzheimer&#8217;s Disease Pipeline<\/b><\/a><\/p>\n<p align=\"justify\"><b>Alzheimer&#8217;s Disease Pipeline Insight \u2013 2025<\/b> report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key Alzheimer&#8217;s Disease companies, including <b>Biogen, AZTherapies, Cerecin, Neurotrope, Synaptogenix, INmune Bio, Cassava Sciences, EIP Pharma, Neuraly, AB Science, Cortexyme, Anavex Life Sciences, Athira Pharma, Time Therapeutics, Denali Therapeutics Inc., Alector Inc., Lexeo Therapeutics, TrueBinding, Inc., Vaccinex Inc., Annovis Bio Inc., Eisai Inc., Hoffmann-La Roche, Ionis Pharmaceuticals, Inc.,\u00a0 Otsuka Pharmaceutical Co., Ltd.,\u00a0 Cognition Therapeutics, Merck Sharp &amp; Dohme LLC, ImmunoBrain Checkpoint, AbbVie, AriBio Co., Ltd.,\u00a0 Oryzon Genomics S.A., Eli Lilly and Company, Neurokine Therapeutics, Excelsior, Seelos Therapeutics, Inc., Janssen Research &amp; Development, LLC, Shanghai Hengrui Pharmaceutical Co., Ltd., reMYND, Alzinova AB, VTBIO Co. LTD, BioVie Inc., Prothena Corporation plc, Coya Therapeutics, Inc., <\/b>among others.<\/p>\n<p align=\"justify\"><b>DelveInsight\u2019s<\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sYhp0yeAahvG8Ek8NWHWumDaZ1hF9GIAcLYxTAOImEQ8RHnCoLB5Oq4GBxDVDT0TyF9i1157UGhuzojTA5hunJ1MlhVASK6PN1IoyD1VqIY5HT8qoxr28f5u2YRKpbt8dAKOjwqesVcvsSkj_reZ6cCmQxdh_mtuZ3kqST8tnfYFTowPJ3TcnTyBNMZmdort\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b> Pharma Competitive Intelligence Service<\/b><\/a><b>: <\/b>Through its CI solutions, DelveInsight provides its clients with real-time and actionable intelligence on their competitors and markets of interest to keep them stay ahead of the competition by providing insights into the latest therapeutic area-specific\/indication-specific market trends, in emerging drugs, and competitive strategies. These services are tailored to the specific needs of each client and are delivered through a combination of reports, dashboards, and interactive presentations, enabling clients to make informed decisions, mitigate risks, and identify opportunities for growth and expansion.<\/p>\n<p align=\"justify\"><b>Other Business Pharmaceutical Consulting Services<\/b><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wvWvtrPdM90slMVRgAbbBFjd-1TF7UdtCmzMr4kIx4Oa4ZuKInBjsR5XVxgRni1crPRNdYxOHdCV56o7RkwBihM4W_ZZkGS1XF-bXBXkkUpLy-iAZpuHHMy56qK9i7OAWwH5Rr21Dgdjy6D8j87LB6TPNs4hq2cRVhDlAD-wdao=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Healthcare Conference Coverage<\/b><\/a><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=vGG0zIyryORR85Npy0RL2xjJadxVQf91A61HIw6ZImzpNyGdYOglLsR44nNRxWW11PNo6cyWQl4MAbjWzG2XysBfJvbAhqvho-QKfWWgkjXkOLYuP3_LF_w3_mVxBG0O16zliKmz4RkkydvLgdYrNjMU07DyhnKA0O5gDOjn9B0=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Pipeline Assessment<\/b><\/a><\/p>\n<p align=\"justify\"><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=wvWvtrPdM90slMVRgAbbBElcchhYd-cVAoWKP9Rnx6V3dWxcFaymD9G_rmZ6MP0vYRXao473uknyJPPIQSNmHDNp6roUSOfHyzbx6DJUwZ6tLRoid1ddMTaIW6SGMgFPgKasFuWYrXISgWVvP6WVrXLq08ya5qw6trQdyZEXS6g=\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Healthcare Licensing Services<\/b><\/a><\/p>\n<p align=\"justify\">Discover how a mid-pharma client gained a level of confidence in their soon-to-be partner for manufacturing their therapeutics by downloading our <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=IT1kg4CZWJY2MKEw--QwZC0ze0yAqFqemd0aXq_NZInkxaiHviFiXdakCr47eQjCFS6aea2yNLs3vaDZx6cQMsWT4_Mo1FsOA58z7UXk4UXHb4bNZjCRJheafXog8stPpbZnKx0rsDEK16oQRl_WHw==\" rel=\"nofollow\" target=\"_blank\" title=\"\"><b>Due Diligence Case Study<\/b><\/a><\/p>\n<p align=\"justify\"><b>About\u00a0DelveInsight<\/b><\/p>\n<p align=\"justify\">DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences.\u00a0<\/p>\n<p align=\"justify\"><b>Connect with us at<\/b><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ZKgRq9Tg3c02fEIpzpvpe4FyGZlKSBo95Dhc9SErugP5PFjDzgmW2Jv7kUsdnQxLV8VXYMAfHskTGDJZMlklzXNXEhTrqZl0RboMHupQB3zNe9uQTiG_EfQIe3egzVUv8n0Xa3rUMdTK7193LYbw_g==\" rel=\"nofollow\" target=\"_blank\" title=\"\"> <b>LinkedIn<\/b><\/a><b>\u00a0<\/b><\/p>\n<pre\/><img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/MmYwNDA0NGQtMjg5MC00ZTJiLTg1MzgtMzg2Mjk0OWIzNTE0LTEyMDQ5MzgtMjAyNS0wOC0xMi1lbg==\/tiny\/DelveInsight-Business-Research.png\" referrerpolicy=\"no-referrer-when-downgrade\"\/>\n            <\/div>\n","protected":false},"excerpt":{"rendered":"<p>New York, USA, Aug. 12, 2025 (GLOBE NEWSWIRE) &#8212; Cannabinoid Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight Cannabinoids are specific chemical compounds found in cannabis, such as tetrahydrocannabinol (THC) and cannabidiol (CBD). Research is increasingly supporting the efficacy of cannabinoids like CBD (cannabidiol) and THC (tetrahydrocannabinol) [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":35713,"comment_status":"","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"default","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","ast-disable-related-posts":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"var(--ast-global-color-4)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"fifu_image_url":"https:\/\/ml.globenewswire.com\/Resource\/Download\/dbcddd65-71dd-4559-8875-ae89ac4f96db","fifu_image_alt":"","footnotes":""},"categories":[11],"tags":[],"class_list":["post-35712","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-globenewswire"],"acf":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/35712","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/comments?post=35712"}],"version-history":[{"count":0,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/posts\/35712\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media\/35713"}],"wp:attachment":[{"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/media?parent=35712"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/categories?post=35712"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/allonlinebanglanewspapers.com\/news\/wp-json\/wp\/v2\/tags?post=35712"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}